Katie O'BRien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katie O'BRien has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Andrew A. Udy
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Intensive Care and Hyperbaric Medicine, The Alfred, Melbourne, Australia
2 shared publications- Bridget Little
Starship Child Health Auckland City Hospital Auckland New Zealand
2 shared publications - Carla Rowe
Nutrition and Dietetics, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia
2 shared publications - Emma Jean Ridley
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Dietetics and Nutrition Department, Alfred Health, Melbourne, Victoria, Australia
2 shared publications - Emma Landorf
Department of Nutrition Women's and Children's Hospital Adelaide South Australia Australia
2 shared publications Ian R. Woodcock
Neurosciences Research, Murdoch Children's Research Institute Melbourne Victoria Australia
2 shared publications
Latest Publications
- 25 June 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 220, 106572
Understanding digital health capability of allied health professionals – a mixed-methods study with content validity analysis
- 25 June 2026
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 220, 106572
Understanding digital health capability of allied health professionals – a mixed-methods study with content validity analysis
- Open Access
- 11 May 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (1) , 198-206
A Retrospective Cohort Study of Nutrition Outcomes in Children With Spinal Muscular Atrophy Type 1 and 2 Treated With Disease Modifying Therapies
Introduction/Aims: Few studies have investigated nutrition as a primary outcome of disease modifying therapy (DMT) in spinal muscular atrophy (SMA). This study aimed to describe nutrition outcomes of DMT in children with SMA 1 and 2. Methods: Children ≤ 18 years old with SMA 1 or 2 treated with DMTs, and untreated children with SMA 1 were included. Retrospective data (anthropometry, feeding, dietetic intervention) were collected from medical records for their duration of care in a tertiary pediatric neuromuscular clinic. Data were analyzed descriptively and reported as median (interquartile range) or percentages. Results: Seventeen treated and 19 untreated children with SMA 1 and 23 treated children with SMA 2 were included. Age (months) at DMT initiation was 3.8 (1.8, 8.7) and 60.3 (28.5, 127.5) for children with SMA 1 and 2 respectively. SMA 1: At 6 months old, weight z ‐score was −0.25 (−1.21, 0.07, n = 7) for treated and −2.67 (−3.09, 0.13, n = 7) for untreated children. Tube feeding was initiated in 82% treated and 89% untreated children; time to initiation (months) was 16.2 for treated children and 6.6 for untreated children. Three treated children ceased tube feeding after 0.6–19 months. SMA 2: Nutrition outcomes were described over 4 years of DMT. All were orally fed. Minimal changes were observed in weight z ‐score trajectories or feeding. Discussion: Nutrition outcomes were improved in treated children with SMA 1 and stable in treated children with SMA 2. Regular dietetic assessment and intervention remain integral to SMA care. Prospective studies are required.
- 11 May 2026
- Published by Wiley in Muscle & Nerve
- Vol. 74 (1) , 198-206
Open AccessA Retrospective Cohort Study of Nutrition Outcomes in Children With Spinal Muscular Atrophy Type 1 and 2 Treated With Disease Modifying Therapies
Introduction/Aims: Few studies have investigated nutrition as a primary outcome of disease modifying therapy (DMT) in spinal muscular atrophy (SMA). This study aimed to describe nutrition outcomes of DMT in children with SMA 1 and 2. Methods: Children ≤ 18 years old with SMA 1 or 2 treated with DMTs, and untreated children with SMA 1 were included. Retrospective data (anthropometry, feeding, dietetic intervention) were collected from medical records for their duration of care in a tertiary pediatric neuromuscular clinic. Data were analyzed descriptively and reported as median (interquartile range) or percentages. Results: Seventeen treated and 19 untreated children with SMA 1 and 23 treated children with SMA 2 were included. Age (months) at DMT initiation was 3.8 (1.8, 8.7) and 60.3 (28.5, 127.5) for children with SMA 1 and 2 respectively. SMA 1: At 6 months old, weight z ‐score was −0.25 (−1.21, 0.07, n = 7) for treated and −2.67 (−3.09, 0.13, n = 7) for untreated children. Tube feeding was initiated in 82% treated and 89% untreated children; time to initiation (months) was 16.2 for treated children and 6.6 for untreated children. Three treated children ceased tube feeding after 0.6–19 months. SMA 2: Nutrition outcomes were described over 4 years of DMT. All were orally fed. Minimal changes were observed in weight z ‐score trajectories or feeding. Discussion: Nutrition outcomes were improved in treated children with SMA 1 and stable in treated children with SMA 2. Regular dietetic assessment and intervention remain integral to SMA care. Prospective studies are required.
- Open Access
- 11 August 2024
- Published by Wiley in Muscle & Nerve
- Vol. 70 (5) , 890-902
Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review
The nutritional implications of spinal muscular atrophy (SMA) are profound. Disease modifying therapies (DMT) have improved clinical outcomes. This review describes the impact of DMT on nutrition outcomes. A systematic search strategy was applied across seven databases until May 2023. Eligible studies measured nutrition outcomes in individuals with SMA on DMT (nusinersen, risdiplam or onasemnogene abeparvovec [OA]) compared to untreated comparators. Nutrition outcomes included anthropometry, feeding route, swallowing dysfunction, dietary intake, dietetic intervention, nutritional biochemistry, metabolism, gastrointestinal issues and energy expenditure. Articles retrieved were screened in duplicate, data were extracted and appraised systematically. Sixty three articles from 54 studies were included; 41% ( n = 22) investigated nusinersen in pediatric participants with SMA type 1. Anthropometry ( n = 18), feeding route ( n = 39), and swallowing dysfunction ( n = 18) were the most commonly reported outcomes. In combined pediatric and adult cohorts, BMI z‐score remained stable post nusinersen therapy. The proportion of children with SMA requiring enteral nutrition was stable post nusinersen therapy. Ability to thrive at age 1.5 years was higher in children treated in early infancy with OA compared to historical controls. Significant heterogeneity existed across study population characteristics and outcome measures. Nusinersen may prevent deterioration in some nutrition outcomes; and OA in early infancy may be associated with improved nutrition outcomes. Timing of DMT initiation is an important consideration for future nutrition research. Studies investigating nutrition as a primary outcome of DMT, using consistent outcome measures are required for nutritional management strategies for this cohort to be appropriately tailored.
- 11 August 2024
- Published by Wiley in Muscle & Nerve
- Vol. 70 (5) , 890-902
Open AccessNutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review
The nutritional implications of spinal muscular atrophy (SMA) are profound. Disease modifying therapies (DMT) have improved clinical outcomes. This review describes the impact of DMT on nutrition outcomes. A systematic search strategy was applied across seven databases until May 2023. Eligible studies measured nutrition outcomes in individuals with SMA on DMT (nusinersen, risdiplam or onasemnogene abeparvovec [OA]) compared to untreated comparators. Nutrition outcomes included anthropometry, feeding route, swallowing dysfunction, dietary intake, dietetic intervention, nutritional biochemistry, metabolism, gastrointestinal issues and energy expenditure. Articles retrieved were screened in duplicate, data were extracted and appraised systematically. Sixty three articles from 54 studies were included; 41% ( n = 22) investigated nusinersen in pediatric participants with SMA type 1. Anthropometry ( n = 18), feeding route ( n = 39), and swallowing dysfunction ( n = 18) were the most commonly reported outcomes. In combined pediatric and adult cohorts, BMI z‐score remained stable post nusinersen therapy. The proportion of children with SMA requiring enteral nutrition was stable post nusinersen therapy. Ability to thrive at age 1.5 years was higher in children treated in early infancy with OA compared to historical controls. Significant heterogeneity existed across study population characteristics and outcome measures. Nusinersen may prevent deterioration in some nutrition outcomes; and OA in early infancy may be associated with improved nutrition outcomes. Timing of DMT initiation is an important consideration for future nutrition research. Studies investigating nutrition as a primary outcome of DMT, using consistent outcome measures are required for nutritional management strategies for this cohort to be appropriately tailored.
- Open Access
Nutrition provision in Australian and New Zealand PICUs: A prospective observational cohort study (ePICUre)
- Open Access
- 9 May 2023
- Published by Elsevier in Australian Critical Care
- Vol. 37 (3) , 490-494
Dietitian and nutrition-related practices and resources in Australian and New Zealand PICUs: A clinician survey
- 9 May 2023
- Published by Elsevier in Australian Critical Care
- Vol. 37 (3) , 490-494
Open AccessDietitian and nutrition-related practices and resources in Australian and New Zealand PICUs: A clinician survey